Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations
- PMID: 9018112
- DOI: 10.1038/sj.onc.1200831
Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations
Abstract
Germline mutations of the RET proto-oncogene, which codes for a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2A (MEN 2A) and 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). MEN 2 mutations have been shown to result in RET oncogenic activation. The RET gene encodes several isoforms whose biological properties, when altered by MEN 2 mutations, have not been thoroughly addressed yet. In this study, we have introduced a MEN 2A mutation (Cys634-->Arg) and the unique MEN 2B mutation (Met918-->Thr) in two RET isoforms of 1114 and 1072 amino acids which differ in the carboxy-terminus part. Herein, we report that each RET isoform activated by MEN 2A or MEN 2B mutation was transforming in fibroblasts and induced neuronal differentiation of pheochromocytoma PC12 cells. However, among the different RET-MEN 2 mutants, the long RET isoform activated by the MEN 2B mutation stimulated the most prominent neurite outgrowth in PC12 cells, while the short RET isoform counterpart elicited a very weak differentiation effect in PC12 cells. We further demonstrate that the morphological changes of PC12 cells caused by constitutively activated RET oncoproteins involved the engagement of a Ras-dependent pathway. These findings provide evidence that the biological properties of RET-MEN 2 mutants depend on the interplay between the RET isoforms and the nature of the activating MEN 2 mutation.
Similar articles
-
RET activation by germline MEN2A and MEN2B mutations.Oncogene. 1995 Dec 7;11(11):2419-27. Oncogene. 1995. PMID: 8570194
-
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.Verh Dtsch Ges Pathol. 1995;79:L-LV. Verh Dtsch Ges Pathol. 1995. PMID: 8600671
-
Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.Biochem Biophys Res Commun. 1997 Aug 28;237(3):747-51. doi: 10.1006/bbrc.1997.7225. Biochem Biophys Res Commun. 1997. PMID: 9299438
-
[The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].Nihon Rinsho. 2004 May;62(5):883-8. Nihon Rinsho. 2004. PMID: 15148813 Review. Japanese.
-
Oncogenic activation of the ret protooncogene in thyroid cancer.Crit Rev Oncog. 1995;6(1):35-46. doi: 10.1615/critrevoncog.v6.i1.30. Crit Rev Oncog. 1995. PMID: 8573606 Review.
Cited by
-
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.Cancers (Basel). 2023 Oct 5;15(19):4865. doi: 10.3390/cancers15194865. Cancers (Basel). 2023. PMID: 37835559 Free PMC article. Review.
-
Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.Biochem Pharmacol. 2023 Oct;216:115751. doi: 10.1016/j.bcp.2023.115751. Epub 2023 Aug 16. Biochem Pharmacol. 2023. PMID: 37595672 Review.
-
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.Cancers (Basel). 2022 Oct 27;14(21):5298. doi: 10.3390/cancers14215298. Cancers (Basel). 2022. PMID: 36358717 Free PMC article. Review.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma.Biomolecules. 2021 Oct 19;11(10):1542. doi: 10.3390/biom11101542. Biomolecules. 2021. PMID: 34680178 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
